Main Article Content
Autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders with variable involvement of the central and peripheral nervous system. A major anesthetic concern in these patients is the potential hypersensitivity to non-depolarizing neuromuscular blockers. Sugammadex is a unique neuromuscular reversal agent which acts by directly binding to aminosteroid non-depolarizing muscle relaxants, such as rocuronium. Sugammadex was first approved in Canada in February 2016. One of its main indications is in patients with muscular or neuromuscular diseases. We demonstrated the use of rocuronium with sugammadex as the reversal agent in a patient with ADCA undergoing laparoscopic bilateral tubal ligation.